Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptase

Current Opinion in HIV and AIDS

Volumn 2, Issue 2, 2007, Pages 103-107

  Götte, Matthias ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Excision; HIV; Nucleoside analogue reverse transcriptase inhibitor; Resistance; Thymidine analogue associated mutation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ARGININE; CARBOVIR; DIDANOSINE; DIDEOXYADENINE; EMTRICITABINE; LAMIVUDINE; LEUCINE; LYSINE; METHIONINE; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALINE; ZALCITABINE; ZIDOVUDINE;

CHEMICAL ANALYSIS; CHEMICAL REACTION; ENZYME INHIBITION; ENZYME STRUCTURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRUS MUTATION;

EID: 34250633201     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3280287a60     Document Type: Review

References (50)

1. Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-15917.
2. Meyer PR, Matsuura SE, Mian AM, et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4:35-43.
3. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 1998; 95:13471-13476.
4. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
5. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-993.
6. Gotte M. Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance. Expert Rev Anti Infect Ther 2004; 2:707-716.
7. Krebs R, Immendorfer U, Thrall SH, et al. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 1997; 36:10292-10300.
8. Sarafianos SG, Das K, Clark AD Jr, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A 1999; 96:10027-10032.
9. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 2004; 36:1687-1705.
10. Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-15917.
11. Meyer PR, Matsuura SE, Mian AM, et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4:35-43.
12. Lacey SF, Reardon JE, Furfine ES, et al. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 1992; 267: 15789-15794.
13. Ray AS, Basavapathruni A, Anderson KS. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002; 277:40479-40490.
14. Smith AJ, Meyer PR, Asthana D, et al. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations. Antimicrob Agents Chemother 2005; 49:1761-1769. This study shows that extracts of human immune cells contain sufficient amounts of pyrophosphate, ATP, and guanosine triphosphate to excise incorporated NRTIs in vitro with purified HIV-1 RT.
15. Smith AJ, Scott WA. The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell. Curr Pharm Des 2006; 12:1827-1841. This review attempts to reconcile the cellular and biochemical requirements for the excision reaction.
16. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
17. Hu Z, Giguel F, Hatano H, et al. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006; 80:7020-7027. This study helps to explain the existence of two different TAM pathways.
18. Isel C, Ehresmann C, Walter P, et al. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J Biol Chem 2001; 276:48725-48732.
19. Gotte M. Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocation. Curr Pharm Des 2006; 12:1867-1877. This work reviews mechanisms of polymerase translocation and its implications for NRTI susceptibility.
20. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11:155-163. This work demonstrates that K65R alone or introduced against a background of TAMs can cause a dramatic reduction in the rates of excision.
21. Boyer PL, Imamichi T, Sarafianos SG, et al. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol 2004; 78:9987-9997.
22. Meyer PR, Matsuura SE, Tolun AA, et al. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46:1540-1545.
23. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75:4832-4842.
24. Sarafianos SG, Clark AD Jr, Tuske S, et al. Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem 2003; 278: 16280-16288.
25. Tong W, Lu CD, Sharma SK, et al. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 1997; 36:5749-5757.
26. Marchand B, Gotte M. Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. J Biol Chem 2003; 278: 35362-35372.
27. Sluis-Cremer N, Arion D, Parikh U, et al. The 3′-azido group is not the primary determinant of AZT responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem 2005; 280:29047-29052.
28. Ray AS, Murakami E, Basavapathruni A, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42:8831-8841.
29. Reid P, MacInnes H, Cong ME, et al. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology 2005; 336:251-264. This work points to a certain degree of natural resistance of HIV-2 to zidovudine. In this study, classic TAMs are not selected in vitro, whereas these mutations rapidly emerge in the context of HIV-1 under identical conditions.
30. Boyer PL, Sarafianos SG, Clark PK, et al. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2: e10.
31. Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L. Mutational patterns associated with the 69 insertion complex in multidrug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine (in press). J Mol Biol 2006.
32. Deval J, Selmi B, Boretto J, et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem 2002; 277:42097-42104.
33. Brehm J, Koontz D, Pathak V, et al. AZT selects mutations in the connection (A371V) and RNase (Q509L) domains of RT that increase AZT resistance in combination with TAMs and reduce susceptibility to other NRTIs [Abstract 125]. XVth International HIV Drug Resistance Workshop. Antiviral Ther 2006; 11:S141.
34. Nikolenko GN, Frankenberry KA, Palmer S, et al. The HIV-1 reverse transcriptase connection domain from treatment-experienced patients contributes to AZT resistance. [Abstract 126]. XVth International HIV Drug Resistance Workshop. Antiviral Ther 2006; 11:S142.
35. Nikolenko GN, Palmer S, Maldarelli F, et al. Mechanism for nucleoside analogmediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A 2005; 102:2093-2098. This work suggests that mutations in the RT-associated RNase H domain may affect the excision reaction. Decreases in RNase H activity may correlate with an increase in excision.
36. Sturmer M, Staszewski S, Doerr HW, et al. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 2003; 47:54-61.
37. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
38. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
39. White KL, Margot NA, Ly JK, et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005; 19:1751-1760.
40. Parikh UM, Koontz DL, Chu CK, et al. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49:1139-1144.
41. Miller MD, Margot NA, Lamy PD, et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr 2001; 27:450-458.
42. Lanier ER, Givens N, Stone C, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004; 5:394-399.
43. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194:651-660. This paper provides strong evidence to suggest that K65R cannot co-exist on a single genome with T215Y/F.
44. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74:3579-3585.
45. Miranda LR, Gotte M, Liang F, Kuritzkes DR. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005; 49:2648-2656.
46. Frankel FA, Marchand B, Turner D, et al. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodefi-ciency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005; 49:2657-2664.
47. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antiviral Ther 2006; 11:155-163.
48. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971-4977.
49. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282:1669-1675.
50. Meyer PR, Smith AJ, Matsuura SE, Scott WA. Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants. Antimicrob Agents Chemother 2006; 50:3607-3614.